By internalizing tumor-associated antigens (TAAs) and processing them through MHC-II pathways, B cells present immunogenic peptides to CD4+ T cells via TCR engagement, crucially licensing dendritic cells for subsequent CD8+ T cell priming through CD40-CD40L costimulatory interactions (14). The gene discussed is CD4; the disease is neoplasm.